ClinicalTrials.gg
Not yet recruitingNCT07659873ADOPT-CPUpdated Nov 16, 2026

Advancing Online Psychology Tools for Chronic Pain

An interventional study of Digital psychology intervention (ADOPT-CP) and Reminder Emails in Fibromyalgia and Chronic Pelvic Pain Syndrome, sponsored by Women's College Hospital. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Women's College Hospital · Not applicable, Interventional, and Supportive care

How we know

Updated Nov 16, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Fibromyalgia with a site in Canada — 4 open to participants now, 4 under way, none of them phase 3. Fibromyalgia · Canada.

Planned enrollment
20th of 37
60 · median 67
Started
2027
the only one that year
No phase
16 of 42
2 open now
Registered
42nd of 42
by date
Lead sponsor
2 of 42
Women's College Hospital

Among the 42 studies in Fibromyalgia with a site in Canada, this one is the 20th largest by planned enrollment of the 37 interventional ones that give a count, is the only one that started in 2027, is one of 16 with no phase, and was the 42nd registered.

Fibromyalgia

1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

4 of the 42 studies in Fibromyalgia with a site in Canada are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Fibromyalgia with a site in Canada, or all of them as a file.
02

Study summary

Chronic pain affects more than 20% of Canadians and is associated with significant impacts on physical function, mental health, and quality of life. Despite efforts to improve access to multidisciplinary pain care through centralized referral systems, many patients continue to experience prolonged wait times before receiving treatment.

This study evaluates a self-guided digital psychological intervention designed to support chronic pain self-management during the waiting period for specialized pain care. The intervention was developed through a collaboration between the Transitional Pain Service and ManagingLife and aims to improve access to evidence-based psychological support, enhance self-management skills, and reduce pain-related distress among individuals living with chronic pain.

Read the detailed description

The Advancing Online Psychology Tools for Chronic Pain (ADOPT-CP) intervention provides participants with access to the Manage My Pain (MMP) platform, including a self-guided Acceptance and Commitment Therapy (ACT)-based digital psychology program and Solace, an artificial intelligence (AI)-enabled conversational support tool for chronic pain. Together, these tools are designed to support pain self-management, emotional coping, and engagement in care.

This study will evaluate the feasibility, acceptability, and preliminary clinical effects of the ADOPT-CP intervention among individuals waiting to access multidisciplinary chronic pain services through the Toronto Academic Pain Medicine Institute (TAPMI). The intervention aims to provide accessible psychological support and self-management resources during the waiting period for specialized pain care.

03

Conditions studied

  • Fibromyalgia
  • Chronic Pelvic Pain Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be deemed to have capacity to provide ;
  2. Must sign and date the informed consent form;
  3. Must state willingness to comply with all study procedures;
  4. Must be at least 18 years of age;
  5. Must be referred to TAPMI;
  6. Must have either fibromyalgia or chronic pelvic pain
  7. Must be on the waitlist at TAPMI;
  8. Must have access to a device that can connect to the Internet with access to email.

Exclusion criteria

Exclusion Criteria:

  1. Currently engaged in psychotherapy or engaged in psychotherapy within the last month at the time of enrolment;
  2. Unable to read, understand, or communicate in English sufficiently to provide and complete the study procedures and questionnaires;
  3. Has active serious mental illness or psychiatric instability that, in the opinion of the research team, may impair the ability to safely participate in the study or to provide informed consent (e.g., active psychosis, active mania);
  4. Has a visual, auditory, or other functional impairment that would prevent independent access to and use of the digital intervention and study procedures on an internet-enabled device.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    The ADOPT-CP intervention includes the Manage My Pain (MMP) app with integrated tools: a customizable pain tracker for monitoring symptoms and generating reports, the Pain Guide with educational content on pain management, a self-guided Acceptance and Commitment Therapy (ACT)-based psychology program, and Solace, an AI-driven conversational agent designed to provide structured, evidence-based psychological support for chronic pain self-management.

    Other: Digital psychology intervention (ADOPT-CP)

  • Active comparator
    Control Group

    The control group will receive treatment as usual plus weekly emailed resources. These resources include materials introduced during the TAPMI orientation session, including Power Over Pain and Progress Over Pain.

    Other: Reminder Emails

Interventions

  • OtherDigital psychology intervention (ADOPT-CP)

    The intervention, Manage My Pain (MMP), is a clinically validated app-based platform that supports individuals with chronic pain in self-managing their symptoms and improving communication and engagement with their care team.

  • OtherReminder Emails

    Weekly emailed pain self-management resources introduced during the Toronto Academic Pain Medicine Institute (TAPMI) orientation

06

What researchers measure

Primary outcomes

  1. Trial feasibility

    Measured according to the CONSORT criteria and include: eligibility rate, recruitment rate, retention rate, measure completion, absence of or minor adverse events.

    Time frame: 10 weeks

  2. Engagement with the digital ADOPT-CP intervention

    Measured via MMP app analytics (usage rates, completion of psychology program, etc.)

    Time frame: 10 weeks

  3. Acceptability and Appropriateness of the ADOPT-CP intervention

    The Treatment Evaluation Inventory-Short Form (TEI-SF) is a self-report measure assessing the acceptability and perceived appropriateness of a treatment or intervention, with higher scores indicating greater treatment acceptability.

    Time frame: 10 weeks

  4. Acceptability and Adherence of the ADOPT-CP intervention

    The Treatment Acceptability/Adherence Scale (TAAS) is a self-report measure assessing perceived acceptability of an intervention and anticipated or actual adherence, with higher scores indicating greater acceptability and adherence.

    Time frame: 10 weeks

  5. Experience using the ADOPT-CP intervention

    a semi-structured interview guide will be used to explore participant experiences, barriers and facilitators to use, acceptability, engagement, and opportunities to refine the digital intervention prior to a larger trial.

    Time frame: 14 weeks

Secondary outcomes

  1. Quality of Life and Pain Interference

    Modified PROMIS-29 Health Domains (Quality of Life and Pain Interference 8a): A validated patient-reported outcome system assessing the impact of health conditions on physical, mental, and social functioning. Higher scores indicate greater pain interference and worse health-related quality of life, while lower scores indicate better functioning and quality of life.

    Time frame: 10 weeks

  2. Pain Acceptance

    Measured by the Chronic Pain Acceptance Questionnaire-Short Form: A validated self-report measure of acceptance of chronic pain. Higher scores indicate greater acceptance of chronic pain, including continued activity engagement and reduced avoidance of pain-related experiences.

    Time frame: 10 weeks

  3. Psychological Flexibility

    Measured by the Acceptance and Action Questionnaire-II (AAQ-II): A validated self-report measure of psychological inflexibility and experiential avoidance. Higher scores indicate greater psychological inflexibility and experiential avoidance, while lower scores indicate greater psychological flexibility.

    Time frame: 10 weeks

  4. Kinesiophobia

    Measured by the Tampa Scale of Kinesiophobia (TSK): a validated self-report questionnaire used to assess fear of movement and fear of re-injury. Higher scores indicate greater fear of movement.

    Time frame: 10 weeks

  5. Pain Resiliency

    Measured by the Pain Resiliency Scale: Measures how well a person can adapt and maintain function despite chronic pain. Higher scores indicate greater resilience in coping with chronic pain, while lower scores indicate reduced adaptive coping.

    Time frame: 10 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — At this time, no external data sharing arrangements or future secondary use arrangements are planned. Study data will be retained and used only for the purposes described in this protocol. If future secondary use or collaboration with internal or external investigators is proposed at a later date, this would occur only in accordance with participant consent, WCH REB requirements, and any required data sharing agreements or institutional approvals. Results from this study may be disseminated through academic publications, presentations, and reports. Only aggregate or de-identified information will be used for these purposes. No participant-identifiable information will be included in any publication or dissemination arising from this study. Study data will not be shared with individuals outside the research team for secondary use.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Oct 2027, 9 months later.

Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 9 months is below that.

Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Jan 2027, on Nov 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Jun 22, 2026
StartEst.
Jan 2027was Oct 2026
Primary completionEst.
Oct 2027
CompletionEst.
Mar 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Oct 2026→Jan 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Oct 2026→Jan 2027
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07659873
Lead sponsor
Women's College Hospital
Responsible party
Sponsor
First posted
Jun 22, 2026
Start date
Jan 2027 (estimated)
Primary completion
Oct 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Adriano Nella, MSc
Contact
Adriano.Nella@wchospital.ca
416-323-6400 ext. 5977
Didem Bozak
Contact
didem.bozak@wchospital.ca
416-323-6008
Tania Di Renna, MD, FRCPC
principal investigator · Women's College Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion